Radhakrishnan Srikanth sold $32K of LUNG

Radhakrishnan Srikanth (Chief Science & Techn. Officer) sold 14,245 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.

Original reporting
SEC EDGAR · Radhakrishnan Srikanth
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The disclosed sale is modest relative to total holdings and unlikely to affect market perception significantly.

02

Market read

Primary insider sale filing; low materiality but provides fresh data for compliance and monitoring.

03

What to watch

Insider retains a large stake (over 300k shares) indicating continued confidence.

Relevance 3/10Novelty 5/10Timing: filed today (2026-09-03)

Background

Pulmonx Corp (LUNG) is a US-listed biotech focused on pulmonary therapies. Insider transactions are disclosed via Form 4.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

SEC Form 4 disclosed that Chief Science & Techn. Officer Radhakrishnan Srikanth sold 14,245 shares of Pulmonx Corp for $32,193.70 on 2026-09-01.

Expected impact

slight short-term downward pressure

Evidence & confidence

Sale size is under $50k and represents a minor portion of insider holdings; market impact is limited.

Market effects

Minimal effect on the biotech sector; insider sales are routine.

No regional impact.

Limited to investors tracking Pulmonx.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Radhakrishnan Srikanth

    Chief Science & Techn. Officer of Pulmonx Corp

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.